{
    "clinical_study": {
        "@rank": "121073", 
        "arm_group": {
            "arm_group_label": "Ferumoxytol-enhanced MRI", 
            "arm_group_type": "Experimental", 
            "description": "This is a single-arm study.  All enrolled patients will have a ferumoxytol-enhanced MRI scan."
        }, 
        "brief_summary": {
            "textblock": "The purpose of this study is to determine the diagnostic accuracy of ferumoxytol-enhanced\n      MRI in detecting lymph nodes that have been invaded by tumor cells in patients with\n      colorectal cancer."
        }, 
        "brief_title": "Diagnostic Accuracy of Ferumoxytol-Enhanced MRI for Detecting Lymph Node Metastases in Colorectal Cancer", 
        "completion_date": {
            "#text": "June 2016", 
            "@type": "Anticipated"
        }, 
        "condition": "Colorectal Cancer", 
        "condition_browse": {
            "mesh_term": [
                "Colorectal Neoplasms", 
                "Neoplasm Metastasis"
            ]
        }, 
        "detailed_description": {
            "textblock": "This study will investigate the accuracy of ferumoxytol-enhanced MRI in detecting lymph\n      nodes that have been invaded by tumor cells in patients with colorectal cancer.  This study\n      will be performed in addition to any ongoing routine care and will not serve as a substitute\n      for any imaging tests that would be routinely performed prior to surgery."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Patients 18 years of age or older with histologically confirmed colorectal cancer\n\n          -  Measureable and/or suspected metastatic nodes on recent prior imaging (CT, MRI, US)\n\n          -  Planned for surgical resection of tumor\n\n        Exclusion Criteria:\n\n          -  Contraindications for MRI\n\n          -  Contraindication or known allergy to ferumoxytol or parental iron products (e.g. iron\n             sucrose, iron dextran, etc.)\n\n          -  Planned chemotherapy or radiation treatment prior to surgical resection of primary\n             tumor\n\n          -  Uncontrolled serious medical illness\n\n          -  Unable or unwilling to give informed consent\n\n          -  Pregnancy\n\n          -  Breastfeeding women\n\n          -  Clinically documented or known risk of primary or secondary iron overloading\n             including history of thalassemia, sickle cell anemia, hereditary hemochromatosis or\n             first-degree relative with known hemochromatosis, multiple transfusions for any\n             reason within the past 5 years, or use of over-the-counter ferrous sulfate without\n             the supervision of his/her doctor"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "40", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "November 5, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01983371", 
            "org_study_id": "CHRMS 14-096"
        }, 
        "intervention": [
            {
                "arm_group_label": "Ferumoxytol-enhanced MRI", 
                "description": "All study patients will receive a dose of ferumoxytol for the MRI.  Ferumoxytol will be administered intravenously at a dose of 6 mg/kg, for a maximum dose of 510 mg.", 
                "intervention_name": "Ferumoxytol", 
                "intervention_type": "Drug", 
                "other_name": "Feraheme"
            }, 
            {
                "arm_group_label": "Ferumoxytol-enhanced MRI", 
                "description": "All study patients will undergo a ferumoxytol-enhanced MRI in addition to any other ongoing care for colorectal cancer.  Histopathologic analysis of lymph nodes will be the gold standard for determining lymph node status.", 
                "intervention_name": "Magnetic Resonance Imaging", 
                "intervention_type": "Other", 
                "other_name": "MRI"
            }
        ], 
        "intervention_browse": {
            "mesh_term": "Ferumoxytol"
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "Yes", 
        "lastchanged_date": "November 12, 2013", 
        "location": {
            "contact": {
                "last_name": "Aida Arapovic", 
                "phone": "802-847-0000"
            }, 
            "facility": {
                "address": {
                    "city": "Burlington", 
                    "country": "United States", 
                    "state": "Vermont", 
                    "zip": "05401"
                }, 
                "name": "Fletcher Allen Health Care"
            }, 
            "investigator": {
                "last_name": "Scott E Potenta, MD, PhD", 
                "role": "Principal Investigator"
            }, 
            "status": "Not yet recruiting"
        }, 
        "location_countries": {
            "country": "United States"
        }, 
        "number_of_arms": "1", 
        "official_title": "Diagnostic Accuracy of Ferumoxytol-Enhanced MRI for Detecting Lymph Node Metastases in Colorectal Cancer", 
        "overall_official": {
            "affiliation": "Fletcher Allen Health Care / University of Vermont", 
            "last_name": "Scott E Potenta, MD, PhD", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Not yet recruiting", 
        "oversight_info": {
            "authority": "United States: Food and Drug Administration", 
            "has_dmc": "No"
        }, 
        "phase": "N/A", 
        "primary_completion_date": {
            "#text": "June 2016", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "measure": "Prospectively evaluate the diagnostic accuracy of ferumoxytol-enhanced MRI in the setting of colorectal cancer with histopathologic analysis as the gold standard.", 
            "safety_issue": "No", 
            "time_frame": "3 years"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01983371"
        }, 
        "responsible_party": {
            "investigator_affiliation": "University of Vermont", 
            "investigator_full_name": "Scott Potenta, MD, PhD", 
            "investigator_title": "Clinical Instructor", 
            "responsible_party_type": "Sponsor-Investigator"
        }, 
        "source": "University of Vermont", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Scott Potenta, MD, PhD", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "December 2013", 
        "study_design": "Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic", 
        "study_type": "Interventional", 
        "verification_date": "November 2013"
    }
}